• Home
  • Advertise
  • Contact Us
Sunday, February 5, 2023
No Result
View All Result
NEWSLETTER
LondonDailyPost.com
12 °c
London
21 ° Fri
18 ° Sat
17 ° Sun
15 ° Mon
  • UK News
  • World
  • Health
  • Business
  • Science
  • Tech
  • Entertainment
  • Sports
  • Lifestyle
  • Travel
  • Politics
  • UK News
  • World
  • Health
  • Business
  • Science
  • Tech
  • Entertainment
  • Sports
  • Lifestyle
  • Travel
  • Politics
No Result
View All Result
LondonDailyPost.com
No Result
View All Result
Home Science

Industry Leader Novozymes OneHealth White Paper on Helicobacter Pylori Research was Officially Released

by Kevin Taylor
May 30, 2022
in Science
3 min read

On May 28, the white paper on Helicobacter Pylori research by OneHealth, an industry leader, was officially released. In recent years, as a human pathogen with nearly half of the global infection rate, the treatment research of Helicobacter Pylori has attracted much attention. OneHealth (the Human Health Department of Novozymes Group) and Follow Your Gut Research Institute jointly released the “White Paper on Pylopass™ Lactobacillus Reuteri DSM 17648 and Helicobacter Pylori” (hereinafter referred to as the “White Paper”). This is the first scientific report on Helicobacter Pylori research led by enterprises in the industry, striving to explore and interpret the key gist and effective treatment methods of Helicobacter Pylori clinical research, and providing theoretical support for clinical treatment of Helicobacter Pylori in China.

According to the “White Paper”, chronic infection of Helicobacter Pylori was listed as a clear carcinogen in the 15th edition of Carcinogen Report released by the US Department of Health and Human Services in December 2021. According to the report of the World Health Organization, the risk of gastric cancer in people infected with Helicobacter Pylori can increase by two to three times, while in developing countries, about 63% of gastric cancer cases are related to Helicobacter Pylori infection.

With the continuous spread of Helicobacter Pylori, major scientific research institutions and medical enterprises around the world are continuously carrying out related scientific research and clinical trials. Many mainstream consensus guidelines at home and abroad point out that Helicobacter Pylori infection should be eradicated. Among them, many studies have shown that specific probiotic strains may help improve the therapeutic effect of eradicating Helicobacter Pylori.

In order to further help the development of health industry and effectively reduce the disease burden of Helicobacter Pylori infection and the risk of gastric cancer in China, OneHealth made full use of Novozymes Group’s scientific research strength and technical reserves, focused on the research and clinical trials of Helicobacter Pylori, and successfully completed the “White Paper”.

In the long run, the value contribution of the “White Paper” is concentrated in three aspects: First, it scientifically demonstrates the infection rate of Helicobacter Pylori in the world and China, deeply analyzes the research literature of Helicobacter Pylori in China, and clarifies the infection rate, annual recovery rate and annual recovery rate by region, population and age; second, the authority shared the prevention, control and treatment methods of Helicobacter Pylori, integrated and analyzed the consensus of the top ten Helicobacter Pylori at home and abroad, and authoritative doctors interpreted the treatment methods; thirdly, the key to clinical research of Helicobacter Pylori, that is, the existing scientific evidence of Pylopass™  (Lactobacillus Reuteri DSM 17648) used in the treatment of Helicobacter Pylori, was deeply interpreted, and its clinical research and application were discussed from the perspective of evidence-based.

As a human health business brand owned by Novozymes, OneHealth has built an elite microbial R&D team around the world, reshaping the definition of a healthy and better life based on data-driven R&D direction screening, accurate health efficacy verification, rigorous scientific research attitude, high-standard in vitro trials and gold-standard clinical trials.

City:Shanghai

Company Name:Novozymes Yikang Biotechnology (Shanghai) Co., Ltd.

Website::https://novozymesonehealth.com/zh/

Email Address:jinxin.wang@shichangbu.com

Contact:Wang Jinxin

Telephone:18017066245

mm

Kevin Taylor

Kevin has been a part of the journey ever since London Daily Post started. He has a special curiosity for events and stories revolving in and around the UK. Kevin brings an uncompromising form of journalistic standard for his audiences.

Next Post

Impact of Bitcoin Trading in Kansas

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Latest News

How Naomi Ekindi’s First Love Became a North Star for Her Modeling Career

February 2, 2023

Alex Grove Shares the Three Domains of Therapy: Coaching, Counseling, and Player Care

February 2, 2023

An Insight into Dr. Steven Kaufman’s Life: An Accomplished Investor and Leader in Real Estate

February 2, 2023

Afize Ibram – assisting travel enthusiasts like you in finding the best fit for your next trip.

February 1, 2023

Most Notable 40 Under 40 Blockchain Entrepreneurs in 2022

February 1, 2023

Dating Brand for Gym-Enthusiasts, FIT FCK, Attracts New Wave Of Millennial Investors

January 31, 2023

AFFIRMING THE EXISTENCE OF A NEWLY DISCOVERED TOMB OF JESUS

January 25, 2023

Mr. Erik Solheim joins Advisory Board of Updapt (an ESG Tech Co.)

January 24, 2023

Carlos Moreno’s Participation in the Genopole in Evry

January 23, 2023

ElectrifAi’s Answer to AI’s Last-Mile Problem

January 21, 2023
  • Home
  • About
  • Team
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Cookie Policy

© 2019. London Daily Post.

No Result
View All Result
  • Home
  • About
  • Team
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Cookie Policy

© 2019. London Daily Post.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In